Ignite Creation Date:
2024-05-05 @ 10:00 AM
Last Modification Date:
2024-10-26 @ 9:05 AM
Study NCT ID:
NCT00005832
Status:
COMPLETED
Last Update Posted:
2015-11-17
First Post:
2000-06-02
Brief Title:
S9924 R115777 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sponsor:
SWOG Cancer Research Network
Organization:
SWOG Cancer Research Network
Study Overview
Official Title:
A Phase II Trial of R115777 NSC 702818 in Patients With Advanced Pancreas Cancer
Status:
COMPLETED
Status Verified Date:
2015-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die
PURPOSE Phase II trial to study the effectiveness of R115777 in treating patients who have locally advanced or metastatic pancreatic cancer
PURPOSE Phase II trial to study the effectiveness of R115777 in treating patients who have locally advanced or metastatic pancreatic cancer
Detailed Description:
OBJECTIVES I Determine the six month survival rate in patients with advanced adenocarcinoma of the pancreas treated with R115777 II Determine the time to treatment failure and confirmed response in this patient population treated with this regimen III Evaluate the frequency and severity of toxicities associated with this treatment regimen in these patients
OUTLINE Patients receive oral R115777 twice daily on days 1-21 Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity Patients are followed every 6 months for 2 years and then annually thereafter
PROJECTED ACCRUAL A total of 21-50 patients will be accrued for this study
OUTLINE Patients receive oral R115777 twice daily on days 1-21 Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity Patients are followed every 6 months for 2 years and then annually thereafter
PROJECTED ACCRUAL A total of 21-50 patients will be accrued for this study
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U10CA032102 | NIH | SWOG | httpsreporternihgovquickSearchU10CA032102 |
| S9924 | OTHER | None | None |